Key result
Exendin-4 reduces VLDL-C and LDL-C levels independently of the LDL receptor in mice.
Why the study?
The acute cholesterol-lowering effects and mechanisms of exendin-4 treatment in Ldlr−/− and C57BL/6J mice were not fully elucidated.
p-value: p=<0.05
AIMS: and C57BL/6J mice. METHODS: and C57BL/6J mice received exendin-4 or saline for 5 days, and serum lipid profiles and hepatic lipid levels were examined. Cholesterol metabolism-related gene expression and protein levels in the liver and ileum and the fecal bile acid (BA) composition were also examined. RESULTS: mice, exendin-4 treatment also significantly decreased hepatic cholesterol levels and fecal BA excretion, decreased hepatic Cyp7a1 mRNA expression, and increased small intestinal Fgf15 mRNA expression. In C57BL/6J mice, exendin-4 treatment significantly decreased small intestinal NPC1L1 levels. CONCLUSIONS: and C57BL/6J mice.
No takes yet. Share an insight, caveat, or question.
Hori et al. (2022) studied Dyslipidemia (n=47). Exendin-4 vs. Saline was evaluated on Serum VLDL-C and LDL-C levels (p=<0.05). Exendin-4 treatment significantly decreased serum VLDL-C and LDL-C levels in a manner that was independent of the LDL receptor in Ldlr-/- and C57BL/6J mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: